NEC Baby Formula Lawsuit Settlement Amounts — April 2026 Update

NEC Baby Formula Settlement Status — April 2026

The NEC Baby Formula litigation has produced two landmark bellwether verdicts that have set clear expectations for what settlements could look like:

Date	Verdict	Defendant	Details
March 2024	$60 million	Abbott Laboratories	First bellwether — Illinois jury found Abbott liable for failing to warn
July 2024	$495 million	Mead Johnson / Reckitt	Second bellwether — largest verdict of the litigation so far

These verdicts have dramatically shifted settlement dynamics. Both defendants are now under significant pressure to resolve cases to avoid further massive jury awards.

Estimated Settlement Ranges

Based on the bellwether verdicts and the nature of the injuries, legal analysts project:

Case Severity	Estimated Range	Typical Scenario
Tier 1 (Catastrophic / Death)	$500,000 — $5,000,000+	Infant death or severe lifelong disability
Tier 2 (Severe)	$300,000 — $1,500,000	Major surgery (intestinal resection), short bowel syndrome, long-term care
Tier 3 (Significant)	$150,000 — $500,000	NEC diagnosis requiring surgery, ongoing medical issues
Tier 4 (Moderate)	$75,000 — $250,000	NEC diagnosis, recovered, minimal long-term issues

Important: These are projections based on bellwether verdicts and comparable pharmaceutical litigation. Actual settlement amounts will depend on individual case facts, severity of injury, and negotiated outcomes.

Why NEC Cases May Settle for High Amounts

Several factors point to substantial settlement potential:

1. Bellwether verdicts set the floor — Juries have shown willingness to award massive amounts
2. Sympathetic plaintiffs — Premature babies and grieving families evoke strong jury sympathy
3. Internal documents — Discovery has reportedly revealed evidence of manufacturer knowledge
4. Long-term damages — NEC complications can last a lifetime, justifying large awards
5. Defendant resources — Abbott (Similac) and Reckitt (Enfamil) are multi-billion dollar companies
6. Multiple defendants — Plaintiffs can pursue claims against both manufacturers

Factors Affecting Individual Settlement Value

• Severity of NEC — Stage of NEC at diagnosis, surgical intervention required
• Long-term outcome — Death, permanent disability, ongoing complications
• Strength of causation — Clear documentation of formula use preceding NEC
• Age of surviving child — Younger children may have higher lifetime damages
• Medical expenses — Total past and projected costs
• Family impact — Loss of earnings, need for caregiver, emotional trauma

Comparable Pharmaceutical Mass Tort Settlements

Litigation	Injury Type	Total Settlement	Average Per Plaintiff
Johnson & Johnson Talc	Ovarian cancer	$8.9 billion (proposed)	$60k — $500k+
Vioxx	Heart attack	$4.85 billion	~$120,000
Risperdal	Gynecomastia	Individual verdicts	$1.5M — $8B (varied)
Bair Hugger	Infection	Individual	$50k — $250k+

Given the bellwether verdicts, NEC cases may settle above many comparable pharmaceutical litigations.

Expected Timeline

1. Current phase: Post-bellwether settlement negotiations
2. Additional bellwethers: More trials expected in 2026
3. Global settlement framework: May be announced once enough verdicts accumulate
4. Payouts: Could begin 1-2 years after a settlement framework
5. Resolution for most claimants: 2-4 years

What You Should Do Now

• File as soon as possible — The bellwether verdicts have created momentum; early filers position themselves well
• Gather medical records — NICU admission records, formula documentation, NEC diagnosis records
• Document ongoing issues — Any continuing health problems or developmental concerns
• Get a free case evaluation — Attorneys are actively reviewing NEC cases at no cost